Active Comparator: Safety Profile

ADVERSE REACTIONS REPORTED IN ≥10% OF PATIENTS TREATED WITH CAYSTON IN THE ACTIVE COMPARATOR TRIAL6

CAYSTON Adverse events occurring during the active comparator period for ≥10%

Additional safety considerations (Active-Comparator period)6

CAYSTON Additional safety considerations (Active-Comparator period)
*Most commonly cough (CAYSTON: n=7/22; TNS: n=4/11) and productive cough (CAYSTON: n=4/22; TNS: n=5/11).
Considered as treatment-related by investigators; most commonly respiratory incidents (CAYSTON: n=19/31; TNS: n=14/17).
Fifteen patients discontinued treatment due to adverse events (CAYSTON: 9; TNS: 1) or unspecified safety and/or tolerability reasons (TNS: 5), most commonly productive cough (CAYSTON: 3) and hemoptysis (CAYSTON: 3).
Learn About CAYSTON'S Mechanism of Action
NEXT